Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Recursion Pharmaceuticals ( (RXRX) ) is now available.
On February 25, 2026, Recursion reported fourth-quarter and full-year 2025 results and a business update, highlighting its first AI-enabled clinical validation in familial adenomatous polyposis (FAP) and continued advancement of five differentiated clinical programs. The company ended 2025 with $754 million in cash and cash equivalents, said it had exceeded prior cost-savings guidance, and now projects a cash runway into early 2028, underscoring disciplined capital allocation while investing in its AI-powered Recursion Operating System and pipeline.
The company also emphasized momentum in its partnerships, including a fifth progress-based milestone with Sanofi in February 2026, bringing total payments from that collaboration to $134 million and supporting a growing joint portfolio of AI-designed immunology and oncology programs. Recursion has additionally received $213 million in upfront and milestone payments from its Roche and Genentech collaboration, where accepted large-scale CRISPR-based Phenomaps in neuroscience and gastrointestinal oncology are generating new biological insights expected to seed early-stage programs from 2026 onward.
The most recent analyst rating on (RXRX) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, ongoing losses, and negative operating cash flow), with only partial support from low leverage. Offsetting factors include a positive earnings outlook focused on multi-year liquidity/runway, expense reductions, and partnership milestones, while technicals are mildly constructive but still below longer-term trend levels; valuation remains unattractive due to a negative P/E and no dividend.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals (Nasdaq: RXRX) is a clinical-stage TechBio company that uses a full-stack, AI-native operating system to decode biology and accelerate drug discovery and development. The company focuses on building an integrated platform that links multimodal biology, precision chemistry and clinical development to generate novel small-molecule therapeutics, particularly in oncology, immunology and neuroscience through both wholly owned and partnered programs. Recursion monetizes its technology via internal pipeline advancement and collaborations with large pharmaceutical partners, positioning itself as a leading AI-driven player in biopharma.
Average Trading Volume: 21,711,037
Technical Sentiment Signal: Sell
Current Market Cap: $1.84B
See more insights into RXRX stock on TipRanks’ Stock Analysis page.